// App-Quantinova.ai

5004 : The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalutamide (E).

Researchers

Presenter

  • Andrew J. Armstrong

Principal Investigators

  • Jun Luo

  • David M. Nanus

  • Paraskevi Giannakakou

  • Russell Zelig Szmulewitz

  • Daniel Costin Danila

  • Patrick Healy

  • Monika Anand

  • Colin Rothwell

  • John Silberstein

  • Giuseppe Galletti

  • Jason Somarelli

  • Santosh Gupta

  • Simon Gregory

  • Howard I. Scher

  • Ryan Dittamore

  • Scott T. Tagawa

  • Emmanuel S. Antonarakis

  • Daniel J. George

Medical Centers

  • Duke Cancer Institute, Duke University Medical Center, Durham, NC

  • Duke University Medical Center, Durham, NC

  • James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, MD

  • Sandra and Edward Meyer Cancer Center, New York, NY

  • Weill Cornell Medicine/Meyer Cancer Center, New York, NY

  • The University of Chicago Medical Center, Chicago, IL

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Duke University, Durham, NC

  • Duke University Center for Human Genetics, Durham, NC

  • Epic Sciences, Inc., San Diego, CA

  • Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD

Locations

  • United States

Companies

  • EPIC SCIENCES, INC.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Androgen receptor variant 7

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Enzalutamide

  • CB-7598

Outcome

  • Positive

Study Design

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT02269982

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved